500 patients67,039 observations150 daysLIVE

Patient P-03251

Synthetic patientONX-7 · Day 110 · 35–44 · F · baseline S14Steering view · 3DOpen companion preview
Therapy response
Stable
Tolerance
Improving
GI state
Unstable
Inflammatory state
Improving
Nutritional resilience
Unstable
Discontinuation risk
73%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S14
  2. Day 58 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 60 SC-12 recommendedSupportive Compound SC-12
  4. Day 61 Patient acceptedStarted SC-12 in the companion
  5. Day 62 GI-04 recommendedGI Support Protocol GI-04
  6. Day 63 Patient acceptedStarted GI-04 in the companion
  7. Day 67 GI symptom burden −13% vs expectedSupportive Compound SC-12
  8. Day 71 No meaningful changeGI Support Protocol GI-04
  9. Day 73 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 58.

Primary contributors, last 14 days
  • GI instability-18
  • Inflammatory activity-11
  • Nutritional resilience+11
  • Toxicity-9
  • Treatment adherence-8

What helped?

  • Supportive Compound SC-12Day 60
    Result: symptom burden −13%
  • GI Support Protocol GI-04Day 62
    Result: no meaningful change
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
68%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 75% showed improvement
  • median effect visible after 5 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Energy level
Daily log
3.2/10
worsening · -0.1 vs previous 14 d
Stress level
Daily log
5.9/10
improving · -0.4 vs previous 14 d
Pessimism score
Daily log
5.4/10
stable · -0.0 vs previous 14 d
Sleep quality
Wearable
37.3/100
stable · +0.8 vs previous 14 d
Libido
Daily log
2.6/10
improving · +0.2 vs previous 14 d
HRV
Wearable
43.1 ms
stable · +1.6 vs previous 14 d
Toxicity
Blood
36.5/100
worsening · +2.6 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →

Heading towards restoration · 32 from the failing basin, 64 from restoration.

Would help
  • ME-01 Monitoring Escalation
    100% improved among 11 similar · onset 3 d · confidence 74%
  • NP-02 Dietary Support Protocol
    57% improved among 14 similar · onset 10 d · confidence 74%
  • DT-01 Dosing / Timing Recommendation
    75% improved among 8 similar · onset 5 d · confidence 74%
  • More protein
    GI -6.4 next day on high-intake days · n 23
Would not help
  • GI-04 GI Support Protocol
    already tried, no meaningful change
  • AD-05 Adherence Support
    only 18% improved among 11 similar
  • Keep fat low
    GI +7.6 next day on high-intake days · n 25
  • Keep histamine low
    GI +6.4 next day on high-intake days · n 18
  • Keep alcohol low
    GI +5.1 next day on high-intake days · n 21
State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

  • Dietary fat load
    +7.6detractor · 95%
  • Histamine load
    +6.4detractor · 95%
  • Protein
    -6.4supporter · 95%
  • Alcohol
    +5.1detractor · 95%
  • Lactose
    +4.1detractor · 91%
  • Caffeine
    -2.2no signal · 34%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Mucosal barrier integrity 80
    • DNAFUT2 non-secretor lowers mucosal fucosylation
    • MicrobiomeAkkermansia low → thinner mucus layer
    • Daily logGI symptom score 66 and rising
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 41/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Autonomic recovery 45
    • WearableResting HR 83 bpm
    • Wearable3,527 steps/day
  • Inflammatory signalling 25
    • BloodInflammatory load index 58
DNA
Fictional pharmacogenomic panel
  • FUT2 rs601338 AA (non-secretor)
    Reduced mucosal fucosylation
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 3 · butyrate capacity 41/100
  • Akkermansia muciniphilaLow
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumNormal
  • EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
HRV
43 ms
Sleep
6.8 h
Steps
2,367
Resting HR
84 bpm
Daily log: GI score 66, nutritional resilience 37, adherence 42.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0343041%S14SC-12improved45
P-0304940%S14GI-04improved49
P-0303739%S14NP-02improved43
P-0312339%S14GI-04improved50
P-0332339%S14GI-04improved48
P-0300338%S08SC-12improved53
P-0334137%S14NP-02improved49
P-0341336%S14ME-01improved48
P-0314635%S14GI-04improved53
P-0334535%S14SC-12improved56
P-0328934%S03SC-12improved54
P-0339034%S14ME-01improved41